Sergej A. Timofeev

Sergej A. Timofeev

Auto-generated profile, based on publicly available information

Sergej A. Timofeev

I.M. Sechenov First Moscow State Medical University — N.V. Sklifosovsky Institute of Clinical Medicine

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2024 in V.F.Snegirev Archives of Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
NNNatalya A. Nikitina
Natalya A. Nikitina
ISIraida S. Sidorova
Iraida S. Sidorova
MRMaria Raigorodskaia
Maria Raigorodskaia
EMEkaterina A. Morozova
Ekaterina A. Morozova
STSergej A. Timofeev
Sergej A. Timofeev
РПРайгородская Мария Павловна
Райгородская Мария Павловна
BACKGROUND: Despite the retentive relevance of preeclampsia (PE) among the main causes of maternal morbidity and mortality, its etiology remains unclear. Despite gaps in its pathophysiology, highly effective methods of prognosis, prevention, and treatment are still not devised yet. In recent years, the use of microRNA molecules that epigenetically control the expression of target genes at the post-transcriptional level received great interest as are they of key importance in the proliferation, differentiation, invasion, migration, and apoptosis of trophoblast cells and regulation of angiogenesis, immune response, and other processes during pregnancy AIM: This study aimed to investigate the epigenetic mechanisms of PE development based on the evaluation of the expression of pathogenetically significant microRNAs in women’s blood plasma. MATERIALS AND METHODS: The study included 62 female patients divided into the main study group (n=42 with PE) and the control group (n = 20 healthy women with uncomplicated pregnancy, childbirth, and post-natal period). All patients have undergone general clinical, laboratory, and instrumental examinations. The expression levels of 15 microRNAs in the blood plasma were evaluated using a quantitative real-time polymerase chain reaction. DIANA miRPath v. 3.0 was used to evaluate the effect of differentially expressed microRNAs on the functioning of signaling pathways. Statistical data analyses were performed using Statistica 6.0. RESULTS: Multidirectional changes in the expression levels of 13 of 15 plasma microRNAs were found in the PE group compared with the control group; however, the expression levels of the following eight microRNAs decreased significantly: hsa-miR-146a-5p (p=0.011), hsa-miR-181a-5p (p=0.015), hsa-miR-210-3p (p=0.031), hsa-miR-517a-3p (p=0.004), hsa-miR-517c-3p (p=0.007), hsa-miR-574-3p (p=0.048), hsa-miR-574-5p (p=0.003), and hsa-miR-1304-5p (p=0.001). The expression levels of hsa-miR-20a-5p (FC=0.39; p=0.049) and hsa-miR-143-3p (FC=0.71, p=0.05) significantly decreased in pregnant women with PE and symptoms of fetal growth retardation (FGR) compared with the subgroup without FGR. No significant differences in the expression level of the analyzed microRNAs were found between the subgroups with moderate and severe PE and early and late PE. The functional evaluation of differentially expressed microRNAs among women with PE, considering the identification of their potential target genes, revealed the dysregulation of 40 signaling pathways and biological processes in which these molecules are involved. CONCLUSION: PE progresses alongside significant epigenetic changes accompanied by changes in the microRNA expression profile, which are associated with cardiovascular and cerebrovascular diseases and placental disorders. The detected differentially expressed microRNAs may be potential diagnostic markers of PE.

31 October 2022 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
NNNikitina N.A. Nikitina
Nikitina N.A. Nikitina
SSSidorova I.S. Sidorova
Sidorova I.S. Sidorova
AAAgeev M.B. Ageev
Ageev M.B. Ageev
TTTimofeev S.A. Timofeev
Timofeev S.A. Timofeev
KKKiryanova M.A. Kiryanova
Kiryanova M.A. Kiryanova
MMMorozova E.A. Morozova
Morozova E.A. Morozova

1 January 2025 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
NNN.A. Nikitina
N.A. Nikitina
ISI.S. Sidorova
I.S. Sidorova
MRM.P. Raigorodskaya
M.P. Raigorodskaya
EME.A. Morozova
E.A. Morozova
STS.A. Timofeev
S.A. Timofeev
NAN.I. Amiraslanova
N.I. Amiraslanova
Objective. To study the role of microRNAs associated with cardiovascular disease (CVD) and placental abnormalities in the development of pre-eclampsia (PE) based on a comparative analysis of their plasma expression levels in pregnant women with PE, fetal growth restriction (FGR) and in healthy controls. Patients and methods. The study included 74 patients: group I (study group) – 42 pregnant women with PE; group II (comparison group) – 12 pregnant women with FGR; group III (control group) – 20 healthy women with uncomplicated pregnancy and labor. General clinical, laboratory and instrumental methods of investigation were performed, and the expression levels of 15 microRNAs in blood plasma were determined by a real-time PCR: hsa-miR-20a-5p, hsa-miR-143-3p, hsa-miR-146a-5p, hsa-miR-181a-5p, hsa-miR-210-3p, hsa-miR-320a-3p, hsa-miR-375-3p, hsa-miR-517a-3p, hsa-miR-517c-3p, hsamiR-574-3p, hsa-miR-574-5p, hsa-miR-1304-5p, hsa-miR-210-5p, hsa-miR-4498, hsa-miR-1972. Results. The statistically significant differential expression of 8 out of 15 microRNAs was found only in pregnant women with PE (low levels of hsa-miR-146a-5p, hsa-miR-181a-5p, hsa-miR-210-3p, hsa-miR-517a-3p, hsa-miR-517c-3p, hsa-miR-574-3p, hsa-miR-574-5p, hsa-miR-1304-5p). Changes in microRNA levels had a similar unidirectional pattern in all clinical variants of PE (early- and late-onset, moderate and severe, with and without VTE). Bioinformatics analysis showed that the differential expression of 8 microRNAs in PE affects a large number of biological processes and signaling pathways (transcriptional regulation, cell adhesion, cell cycle, cell proliferation and apoptosis, organ and system development, metabolic processes, modulates immune system functions, affects many signaling pathways, including TGF-b, HIF-1, FoxO, Hippo, p53-mediated pathway, etc.). Conclusion. The development of PE, regardless of its clinical phenotype, is accompanied by dysregulation of microRNAs associated with cardiovascular and cerebrovascular diseases, metabolic disorders, inflammation, and involved in many cellular processes (proliferation, invasion, migration, apoptosis, and cell cycle) in trophoblast tissue. Key words: pregnancy, fetal growth restriction (FGR), microRNAs, pre-eclampsia, signaling pathways, trophoblast

24 December 2024 in Russian Bulletin of Obstetrician-Gynecologist
Verified
Journal Article
Closed access
NNN.A. Nikitina
N.A. Nikitina
ISI.S. Sidorova
I.S. Sidorova
MRM.P. Raigorodskaya
M.P. Raigorodskaya
EME.A. Morozova
E.A. Morozova
STS.A. Timofeev
S.A. Timofeev
NAN.I. Amiraslanova
N.I. Amiraslanova
Objective. To study the molecular mechanisms of fetal growth restriction and preeclampsia de-velopment based on a comparative analysis of the placental microRNA expression profile. Materials and methods. The study included 60 patients: Group 1 included 20 pregnant women with preeclampsia (PE) (main group), Group 2 (comparison group) included 20 pregnant women with fetal growth retardation (FGR), Group 3 included 20 healthy women with uncomplicated pregnancy and timely delivery (control group). All patients underwent general clinical, laboratory and instrumental studies, and the expression of 15 microRNAs in placental tissue was deter-mined: hsa-miR-20a-5p, hsa-miR-143-3p, hsa-miR-146a-5p, hsa-miR-181a-5p, hsa-miR-210-3p, hsa-miR-320a-3p, hsa-miR-375-3p, hsa-miR-517a-3p, hsa-miR-517c-3p, hsa-miR-574-3p, hsa-miR-574-5p, hsa-miR-1304-5p, hsa-miR-210-5p, hsa-miR-4498, hsa-miR-1972. Statistical data processing was performed using the licensed software package SPSS 26 and Statistica 12. Results. In the group with PE, compared with the control group, a statistically significant 10-fold decrease in the expression of microRNA hsa-miR-4498 (FC=0.11; p=0.04) and its increase in microRNA hsa-miR-20a-5p, hsa-miR-143-3p, hsa-miR-146a-5p (p≤0.05) were revealed. In the comparison group, the expression of hsa-miR-210-5p, hsa-miR-574-3p, hsa-miR-1972 was statis-tically significantly reduced compared with these indicators in the control group. In the main group, a statistically significant decrease in 5 microRNAs (hsa-miR-20a-5p, hsa-miR-143-3p, hsa-miR-210-5p, hsa-miR-574-3p, hsa-miR-1972) was recorded relative to the comparison group. With the development of PE in combination with FGR, a statistically significant decrease in the expression of 6 microRNAs (hsa-miR-146a-5p, hsa-miR-181a-5p, hsa-miR-210-5p, hsa-miR-320a-3p, hsa-miR-574-5p, hsa-miR-4498) was recorded compared to that in PE without fetal growth retardation. When comparing the levels of placental microRNAs in patients with moder-ate and severe PE, no statistically significant difference in microRNA expression among the ana-lyzed molecules was revealed. Conclusion. Pregnant women with PE and fetal growth retardation, compared to patients with physiological pregnancy, have a clear dysregulation of a number of placental microRNAs, which are potential regulators of many signaling pathways and biological processes (cell cycle, embryo-genesis, carcinogenesis, infectious and inflammatory processes, response to hypoxia, immune dysregulation, antiangiogenic and proinflammatory state). The obtained results confirm the muti-directionality of the etiopathogenetic links in the development of PE and IGR and similar final mechanisms for the development of early and late PE at the stage of clinical manifestations.

25 July 2022 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
SSSidorova I.S. Sidorova
Sidorova I.S. Sidorova
NNNikitina N.A. Nikitina
Nikitina N.A. Nikitina
AAAgeev M.B. Ageev
Ageev M.B. Ageev
TTTimofeev S.A. Timofeev
Timofeev S.A. Timofeev
MMMorozova E.A. Morozova
Morozova E.A. Morozova

1 January 2025 in Voprosy Ginekologii, Akušerstva i Perinatologii
Verified
Journal Article
Closed access
NNN.A. Nikitina
N.A. Nikitina
ISI.S. Sidorova
I.S. Sidorova
DAD.A. Averinskaya
D.A. Averinskaya
EME.A. Morozova
E.A. Morozova
STS.A. Timofeev
S.A. Timofeev
NAN.I. Amiraslanova
N.I. Amiraslanova
Objective. To identify potential molecular biomarkers involved in the pathophysiology of pre-eclampsia (PE) based on the comparative analysis of placental microRNA profile in PE and normal pregnancy. Patients and methods. The study included 30 patients who were divided into two groups: group I – 15 pregnant women with PE (study group), group II – 15 healthy women without pregnancy and labor complications (control group). The placental microRNA profile was studied by NGS (Next-Generation Sequencing). The DIANA miRPath v.4.0 and KEGG (“Kyoto encyclopedia of genes and genome”) databases were used to analyze the placental microRNAs expressed in PE. Results. In each placental tissue sample, 890 to 1000 microRNAs were detected. Significant differences in the expression levels of 90 microRNAs were found in the group of patients with PE. Further calculation of odds ratios (ORs) for PE risk based on logistic regression allowed us to identify 14 most significant placental microRNAs involved in the development of this pregnancy complication: overexpression of 6 microRNAs (hsa-miR-103a-3p, hsa-miR-193a-3p, hsa-miR-3179, hsa-miR-374b-Cпеци5p, hsa-miR-4433b-5p, hsa-miR-487b-5p) and low expression levels of 8 microRNAs (hsa-miR-18a-5p, hsa-miR-361-3p, hsamiR-374a-3p, hsa-miR-451a, hsa-miR-516a-5p, hsa-miR-518e-3p, hsa-miR-523-3p, hsa-miR-5582-3p). The correlation analysis with clinical data, characteristics of PE course and outcomes, as well as functional potential of the studied microRNAs indicate the possibility of considering 5 microRNAs as biomarkers of PE (hsa-miR-103a-3p, hsa-miR-18a-5p, hsa-miR-487b-5p, hsa-miR-523-3p, hsa-miR-5582-3p). Conclusion. The development of PE is accompanied by the dysregulation of placental microRNAs involved in fetal growth and development, placental morphogenesis and function, and in many signaling pathways and biological processes (invasion, proliferation, cell differentiation, apoptosis, angiogenesis, hypoxia response reactions, inflammation, immune response). It is also associated with cardiovascular, renal, endocrine, and metabolic disorders. Key words: microRNA, sequencing, placenta, pre-eclampsia, transcriptome